Helena Yu
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
1 more share only the name and are not shown
Trial papers
947
PubMed author-name match
Trials
Studies that name Helena Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07535437 · A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerMemorial Sloan Kettering Cancer Center · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT04965090 · A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)Memorial Sloan Kettering Cancer Center · completed · Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04410796 · Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersMemorial Sloan Kettering Cancer Center · recruiting · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03810807 · Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerMemorial Sloan Kettering Cancer Center · completed · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03567642 · A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersMemorial Sloan Kettering Cancer Center · active not recruiting · Lung Cancer · principal investigator
- Ph1/Ph2NCT03076164 · A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibMemorial Sloan Kettering Cancer Center · completed · Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic · principal investigator
- Ph1/Ph2NCT02803203 · Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersMemorial Sloan Kettering Cancer Center · completed · Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers · principal investigator
- N/ANCT02450591 · Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsMemorial Sloan Kettering Cancer Center · completed · Oligometastatic Lung Adenocarcinoma · principal investigator
- N/ANCT02186236 · Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer PatientsMemorial Sloan Kettering Cancer Center · completed · Lung Cancer, Colorectal Cancer · principal investigator
- Ph1/Ph2NCT02155465 · Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibMemorial Sloan Kettering Cancer Center · completed · Lung Cancer · principal investigator
- Ph1NCT01967095 · Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerMemorial Sloan Kettering Cancer Center · completed · EGFR-Mutant Lung Cancer · principal investigator
- N/ANCT00579683 · Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung CancerMemorial Sloan Kettering Cancer Center · completed · Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Drivers of histologic transformation in EGFR-mutant lung cancerR01CA264078 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $404,888 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:10 UTC. The ranking covers the 200 most relevant of 947 PubMed records, and a shared surname and initials can bring in a namesake. All 947 on PubMed
- 829 citationsRCR 26.1
- 561 citationsRCR 18.1
- Myopia Prevention and Outdoor Light Intensity in a School-Based Cluster Randomized Trial.Ophthalmology · 2018427 citationsRCR 30.4
- 425 citationsRCR 20.2
- Kidney damage causally affects the brain cortical structure: A Mendelian randomization study.EBioMedicine · 2021221 citationsRCR 13.9
- The Electrical Isolation of the Left Atrial Posterior Wall in Catheter Ablation of Persistent Atrial Fibrillation.JACC Clin Electrophysiol · 2019166 citationsRCR 9.8
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.Muscle Nerve · 2021147 citationsRCR 9.2
- Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.J Clin Oncol · 2022137 citationsRCR 9.5
- XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.Crit Care Med · 2019136 citationsRCR 7.1
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nat Med · 2024130 citationsRCR 16.1